Sweden-based AlzeCure Pharma AB (STO: ALZCUR) has received full delivery of the USD 10 million upfront payment under its collaboration and out-licensing agreement with Eli Lilly, completing the initial transaction for global rights to the preclinical gamma-secretase modulator (GSM) ACD680 and its Alzstatin program. The deal, originally announced June 9, 2026, carries potential milestone payments that could push total deal value beyond USD 1 billion, plus tiered mid-single-digit royalties on net sales. Lilly (NYSE: LLY) assumes responsibility for all clinical development and commercialization globally.
ACD680 is a small-molecule GSM described by AlzeCure as selectively shifting gamma-secretase cleavage to reduce production of the aggregation-prone Aβ42 peptide while increasing shorter, non-toxic Aβ37 and Aβ38 species. The compound remains at preclinical stage, with no clinical trial identifiers or regulatory designations disclosed. The GSM class carries historical baggage from first-generation gamma-secretase inhibitors — including semagacestat, which failed due to Notch-pathway toxicity — but second-generation modulators are designed to preserve normal gamma-secretase signaling while selectively altering APP cleavage.
The closing completes a rapid dual out-licensing of AlzeCure's entire Alzheimer's portfolio. Less than three weeks after the Lilly agreement, AlzeCure out-licensed its NeuroRestore ACD856 program to QuantumCell ApS — a Denmark-based company backed by Lundbeckfonden and Novo Holdings — for USD 12 million upfront, including a USD 5 million equity investment in AlzeCure at a 30% premium, against potential milestones exceeding USD 2.2 billion. QuantumCell completed its own upfront payment on August 12, six days before the Lilly payment was confirmed. Together, the two transactions convert AlzeCure from a development-stage company into primarily a royalty and milestone recipient, with its remaining wholly owned pipeline centered on pain assets including TrkA-NAM ACD137 and ACD440, the latter of which holds orphan drug status in both the US and EU.